Document is current
Any future updates will be listed below
-
Authors
Schuster, Viktoria https://orcid.org/0000-0002-6016-8337
Dann, Emma https://orcid.org/0000-0002-7400-7438
Krogh, Anders https://orcid.org/0000-0002-5147-6282
Teichmann, Sarah A. https://orcid.org/0000-0002-6294-6366
-
Funding
Funding for this research was provided by:
Wellcome Trust (WT206194)
Novo Nordisk Fonden (NNF20OC0062606, NNF20OC0063268, NNF20OC0059939)
- License Information
-
More Information
Article History
Received: 13 May 2024
Accepted: 3 October 2024
First Online: 20 November 2024
Competing interests
: S.A.T. is a Scientific Advisory Board member of ForeSite Labs, Qiagen, OMass, and is a co-founder and equity holder of TransitionBio and EnsoCell Therapeutics, a non-executive director of 10x Genomics, as well as a part-time employee of GlaxoSmithKline. A.K., E.D., and V.S. declare no competing interests.
